NEW YORK, March 3, 2021 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage
biopharmaceutical company, today provided an update on preclinical
study on HT-002 for the prevention and/or treatment of Sars-CoV-2,
or COVID-19.
The novel peptide therapeutic, HT-002, in which Hoth
Therapeutics holds an exclusive license, targets inhibition of
SARS-COV-2 virus cell infection is under development at
Virginia Commonwealth University
("VCU"). There are 3 leading peptide candidates that have been
optimized chemically to maximize the potential viral inhibition.
These candidates are currently under investigation using live
SARS-CoV-2 viral inhibition assays to determine the level of viral
inhibition in vitro. One of the peptide candidates has demonstrated
low level viral inhibition assay with no toxicity to the host cell.
One or more of the optimized peptide candidates may be combined to
achieve maximum viral inhibition.
Peptide sequence modeling analysis supports that these optimized
peptides could be effective against the emerging UK and South
African SARS-CoV-2 strain variants.
The research is being led by inventor Michael H. Peters, Ph.D., Professor, Department
of Chemical and Life Science Engineering at VCU, College of
Engineering. Hoth Therapeutics continues to fund Dr. Peters
research through a sponsored research agreement with Virginia
Commonwealth University (VCU).
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc.
is a clinical-stage biopharmaceutical company focused on developing
new generation therapies for unmet medical needs. Hoth's pipeline
development is focused to improve the quality of life for patients
suffering from indications including atopic dermatitis, skin
toxicities associated with cancer therapy, chronic wounds,
psoriasis, asthma, acne, and pneumonia. Hoth has also entered into
two different agreements to further the development of two
therapeutic prospects to prevent or treat COVID-19. To learn
more, please visit www.hoththerapeutics.com.
Forward-Looking Statement
This press release includes forward-looking statements based upon
Hoth's current expectations which may constitute forward-looking
statements for the purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995 and other federal
securities laws, and are subject to substantial risks,
uncertainties and assumptions. These statements concern Hoth's
business strategies; the timing of regulatory submissions; the
ability to obtain and maintain regulatory approval of existing
product candidates and any other product candidates we may develop,
and the labeling under any approval we may obtain; the timing and
costs of clinical trials, the timing and costs of other expenses;
market acceptance of our products; the ultimate impact of the
current Coronavirus pandemic, or any other health epidemic, on our
business, our clinical trials, our research programs, healthcare
systems or the global economy as a whole; our intellectual
property; our reliance on third party organizations; our
competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans and
expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section entitled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-provides-update-on-novel-peptide-covid-19-therapeutic-ht-002-preclinical-studies-301239440.html
SOURCE Hoth Therapeutics, Inc.